JAK inhibitors: promising for a wider spectrum of autoimmune diseases?

Affiliations

¹ First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, 11527, Athens, Attiki, Greece. Electronic address: mtektonidou@med.uoa.gr.

Comment

Maria G Tektonidou. Lancet. 2019.

. 2019 Dec 7;394(10214):2047-2048.

doi: 10.1016/S0140-6736(19)32681-9. Epub 2019 Nov 12.

¹ First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, 11527, Athens, Attiki, Greece. Electronic address: mtektonidou@med.uoa.gr.

No abstract available

Comment on

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. van der Heijde D, et al. Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12. Lancet. 2019. PMID: 31732180 Clinical Trial.